Location History:
- Indianapolis, IN (US) (1997 - 1999)
- Mooresville, IN (US) (2008)
Company Filing History:
Years Active: 1997-2008
Title: Mark J Zweifel: Innovator in Glycopeptide Antibiotics
Introduction
Mark J Zweifel is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of glycopeptide antibiotics, holding a total of 7 patents. His work focuses on developing innovative methods and compounds that enhance antibacterial activity.
Latest Patents
Among his latest patents is the invention titled "Selective N-acylation of A82846 glycopeptides analogs." This invention provides a process for selectively acylating an A82846A, A82846B, A82846C, or PA-42867-A glycopeptide at the N1, N2, or N3 positions, along with the monoacylated compounds prepared from these processes. Another notable patent is related to "Glycopeptide antibiotic derivatives," which presents derivative compounds that exhibit antibacterial activity against a wide variety of bacteria, including those resistant to vancomycin. Methods for making and using these glycopeptide antibiotic derivative compounds are also included in this patent.
Career Highlights
Mark J Zweifel is currently associated with Eli Lilly and Company, where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in advancing the understanding and application of glycopeptide antibiotics.
Collaborations
Throughout his career, Mark has collaborated with notable colleagues, including Michael J Rodriguez and Robin D Cooper. These collaborations have contributed to the development of groundbreaking antibiotic solutions.
Conclusion
Mark J Zweifel's contributions to the field of glycopeptide antibiotics highlight his role as a leading inventor. His innovative patents and collaborations continue to impact the pharmaceutical industry positively.